ND P HARMA
&
B IOTECH
2013 FACT BOOK
Becoming ND Pharma & Biotech ND Pharma & Biotech is a leader in addressing these chanllenges, with an expanden focus and horizon on biologics and targeted medicine. We use our knowledge and expertise to develop therapies and products that address difficult conditions affecting significant populations. Our priority is “patient needs come first” to to help them to reach and control healthier lives, as part of the plans to make life better. ND Pharma & Biotech has a solid scientific foundation, financial muscle and a strong and ever-evolvng product portfolio. We are on the way of a series of new product pipeline that provide us with the resources we need today and form the long term thinking period.
ND Pharma & Biotech IS A GLOBAL BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPMENT OF ADVANCED THERAPIES THAT WILL ADDRESS SOME OF THE WORLD´S MORE COMPLEX AND SERIOUS DISEASES, HELP TO REMOVE CHEM-TOX FROM FOOD CHAIN, AND MAKE OUR LIFE A HEALTHY, BETTER AND HAPPY ONE.
Our senior leadership really understood how to manage a growing company and the relatedindividuals that in one way or another are working to make this company the great one it is. We agreed to call them collaborators. Our global footprint reach customers in 45 countries around the globe.
2013 FACT BOOK
OUR THERAPEUTIC FOCUS ND Pharma & Biotech products and pipeline are focused on a wide range of serious conditions that affect significant patient populations, including but not limited to:
ND Pharma has supported over 50 Investigational New Drug (IND) filings and over 5 New Drug Applications
• Hepatitis C
• Resistent Infections
(NDA), Abbreviated New
• Rheumatoid arthritis
• Refractary Schizophrenia
Drug Applications (ANDA)
• Psoriasis
• Herpes symplex T·II
and New Animal Drug
• Multiple sclerosis
• Treatment Resistant Depression
Applications (NADA) over
• Alzheirmer´s disease
• Trigeminal Neuralgia
the past 3 years.
• Parkinson´s disease
• Head & Facial Pain Syndromme
• Spondyloarthropaties
• Insulin-Target
• Multiple myeloma
• Inhaled III Generation Ergotamines
• Endometriosis
ND Pharma specializes in all phases of pharmaceutical development – from critical pre-formulation studies to commercial product lifecycle management. Our comprehensive services are fully integrated to help our clients get the most out of their portfolio.
ND Pharma Markets WE CREATE LEADING PRODUCTS WE SPREAD AROUND THE WORLD
•NOOPEPTIL •NOOGLUTIL •AVIVA •GLICOSPART •TANCREAM
•CEREON
•ZELITEM
•KALKLO FORTE
•PSORIACRIM
•KALKLO Depot
•BACTERSKIN
•ALVAR·DUO
•ND 507 LifeSaver •ZELIPLON·Mono •ACNIFOL
•OSTEOTECH
•HUMTREM
•FORTECH
2013 FACT BOOK
OUR COMPELLING ACHIEVEMENTS ND Pharma & Biotech has a compelling record of achievements that are willing to led us to rise a new product pipeline of advanced treatments that will address unmet medical and health conditions and some of the most pressing and complex diseases people around the world are facing now. We serve also as R+D+i to some other companies with less or none possibilitties of development. We have developed proprietary technologies and methods to help us better prioritize our pipeline and investments so that we can more quickly advance most promising compounds from laboratory to clinic. ND Pharma & Biotech multipled our library of CE´s (Chemical Entitiess) with actually over 150.000 NCE´s (Novel chemical entities),+ 60.000 Fine chemicals and API´s on repository and +11.000 products on stock, pre-packed and ready to go.
2013 FACT BOOK
OUR PARTNERSHIPS At ND Pharma & Biotech, we understand that progress often comes more quickly working together than alone. That´s why we collaborate with external researchers, other companies, medical societies, patient advocates, and many other stakeholders to gain a better understanding of how we can make the most significant contributions in our areas of focus.
2013 FACT BOOK
During our first several years, ND PHARMA & BIOTECH operated as a "virtual" company which comprised a geographically diverse network of academic scientists, healthcare professionals, patient advocacy groups and business people. Although the company has matured and many of our employees are based at our headquarters in London, UK we’ve remained true to our origins as a collaborative enterprise — both within the company and with external partners with whom we share a sense of mission. This unusually high level of teamwork has contributed substantially to our ability to innovate successfully, from product identification to preclinical, clinical and commercial development. As you browse through ndpharmabiotech.com and learn more about our company and the people who are working to bring important new therapies to people with different diseases and disorders, I hope what stands out is that our sense of commitment to medical innovation and patient benefit is as strong today as it was back in our foundation years as young researchers and innovation leaders, when we started with two employees and a vision in our travel suitcase. We´ve spent a number of years dedicated to clinical work, research, development and teaching activities, as dedicated teachers, clinicians and investitigators. From that primitive times, we have conserved our passion, drive, devotion and the ilussion of contributing to improve the lives of those that matters to us, our beloved ones. This is why we do what we do, to make life better. This is why we are what we are now. ND Pharma & Biotech, true and pure spirit of a family company.
2013 FACT BOOK
ND Pharma & Biotech Company Ltd. Registered Address: 11 Church Road, Great Bookham Surrey, England United Kingdom
General Information and enquiries info@ndpharmabiotech.com ND Pharma & Biotech Co. (Worldwide Service) E.M.E.A. (Europe, Middle East and Africa) ndpharmabiotech@europe.com THE AMERICAS (NORTH & CENTRAL) ndpharmabiotech@usa.com LATIN AMERICA & CARIBBEAN ndpharmabiotech@samerica.com ASIA-PACIFIC REGION ndpharmabiotech@asia.com
Important information about The Company
DESCRIPTION OF THE BUSINESS
ND PHARMA & BIOTECH is a Private Company Limited by Shares.
Principal activity of the company in the research, development and
The Company Directors esteemed the public launch of the company
innovation, within every area of science and technology, especially
(IPO) within the AIM of the London Stock Exchange, could be
biopharmaceutical, food-nutrition-healthcare-agribusiness and other
consistent with previsions to the mid-year of 2015. In the meanwhile
related, including but not limited to this areas, with divisional societies and
The Company and company directors, are making every possible
subsidiaries in some other fields of innovation and research, from water
effort to accomplish with existing regulations and maximun
technologies to the manufacturing of consumer products, licensing of
transparence to offer the interested or potential investors every
patents, brands, industrial secrets, utility models and any other form of
possibility of taking contact with the company, it´s values and
proprietary IP.
objectives, mission, vision and proceedings, market areas and sectors, products, etc. to let them to get formed a complete frame prior to IPO and/or any other purposed public market initiative. Despite this it must be clear that company shares are not on sale, unless private funding interest from certain investors that are part of the shareholders from the very beginning and true company incorporation. Other investment options exists for company divisional societies and subsidiaries, that may be considered and/or treated on a case by case bais. No total or partial information contained within this website and/or other company websites and informational or
COUNTRY OF INCORPORATION AND MAIN COUNTRY OF OPERATIONS ND PHARMA & BIOTECH LTD., is incorporated in England & Wales with Registration Number 08273797 wich is also the main country of operations for administrative and social purposes. The Company is developing active industrial and commercial promotion and activity in several regions characterized by geographical areas, Europe, Africa and Mid-East Countries (EMEA), Asia, and The Americas, with representatives in these areas established and other in constant expansion and growing.
corporate leaflets, flyers or webpages should be taken as invitation to treat or buy offer of shares, stocks and/or any other form of participation within the company capital, neither a pre-offer facing a
CURRENT CONSTITUTIONAL DOCUMENTS
future initial public offering (IPO). The company reserves every right over the shares, information, or any other considered within the private sphere of company operations. Notwithstanding, this information is intended to offer transparent image and in compliance
Memorandum and Articles of Association Bribery Act - Anti Bribery Policy
with good company practices manuals for public companies.
Certificate of Incorporation
INSTITUTIONAL AND INVESTOR´S RELATIONS
Protocols
Ms. Mary S. Kay, Chief Financial Officer cfo@ndpharmabiotech.com 2013 FACT BOOK
2013 FACT BOOK
Š2013 ND Pharma & Biotech Co.
ND Pharma & Biotech Co.
www.ndpharmabiotech.com
Please contact s with your questions and comments: ND Pharma & Biotech General mail: info@ndpharmabiotech.com
ND Pharma & Biotech Making Life Better